Medicinova (MNOV) Total Non-Current Liabilities (2018 - 2026)
Medicinova (MNOV) posted quarterly Total Non-Current Liabilities of $4.0 million for Q4 2025, up 26.52% year-over-year from $3.2 million in Q4 2024, and up 13.0% quarter-over-quarter from $3.5 million in Q3 2025.
Medicinova (MNOV) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Total Non-Current Liabilities for 8 consecutive years, with $4.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 26.52% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (up 26.52% YoY), while the FY2025 annual figure was $4.0 million, up 26.52% from the prior year.
- Total Non-Current Liabilities grew to $4.0 million in Q4 2025 per MNOV's latest filing, from $3.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $4.7 million in Q3 2022 and bottomed at $2.3 million in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged $3.4 million across 5 years, with a median of $3.2 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 36.5% — and 2025, when it grew 26.52%.
- Medicinova's Total Non-Current Liabilities stood at $3.0 million in 2021, then gained by 11.68% to $3.4 million in 2022, then grew by 2.7% to $3.5 million in 2023, then slipped by 9.19% to $3.2 million in 2024, then grew by 26.52% to $4.0 million in 2025.
- Business Quant data shows MNOV's Total Non-Current Liabilities at $4.0 million in Q4 2025, $3.5 million in Q3 2025, and $2.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Medicinova | 68.66 Mn | 68.66 Mn | 317,759.00 | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 3.48 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 3.02 Mn |
| Mar 31, 2023 | 2.92 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 4.73 Mn |
| Jun 30, 2022 | 4.04 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 3.03 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 4.36 Mn |